Everolimus and long-term decline in renal function after liver transplantation: real-life experience with measured GFR
- 1 June 2020
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 55 (6) , 718-724
Abstract
Switching from calcineurin-inhibitors (CNI) to everolimus >6–12-months after liver transplantation (LT) seems inefficient in improving renal function, but whether everolimus halts further renal-function decline compared to low-dose CNI remains unclear. In a retrospective single-center study of everolimus after LT (2008–2016) with routine measured glomerular filtration rates (mGFR; 51Cr-EDTA- or iohexol clearance), we compared by propensity-score matching everolimus therapy to low-dose CNI therapy. The study comprised 36 patients with everolimus introduced on average 22 months post-LT (range 2–105 months, median follow-up 3.4 years), and 36 matched controls. Everolimus introduction was associated with a mean improvement in mGFR of 7 mL/min up to 1 year (p = .003), restricted to patients switched 5 ng/mL. The differences between the everolimus group and controls in delta-mGFR from baseline to 1 year (7.3 vs 4.3 mL/min, p = .25) or 1-year to last follow-up (−0.8 vs −0.2 mL/min/year, p = .71) were non-significant. Proportions with mGFR decline >3 mL/min/year were similar between groups (11% and 14%, p = 1.00). Everolimus was stopped in three patients (8%), and acute rejection occurred in 17%. In conclusion, despite an early improvement in renal function after everolimus introduction, we found no evidence that everolimus halts the long-term mGFR decline compared to continued low-dose CNI therapy. Due to retrospective design, small sample size and heterogenous characteristics, definite conclusions require prospective studies.Keywords
This publication has 20 references indexed in Scilit:
- Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver TransplantationTransplantation, 2016
- Differences in long‐term survival among liver transplant recipients and the general population: A population‐based nordic studyHepatology, 2015
- Chronic kidney disease and associated mortality after liver transplantation – A time-dependent analysis using measured glomerular filtration rateJournal of Hepatology, 2014
- Native kidney function following liver transplantation using calcineurin inhibitors: single‐center analysis with 20 years of follow‐upClinical Transplantation, 2013
- Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized TrialAmerican Journal of Transplantation, 2012
- Use of Sirolimus in Liver Transplant Recipients with Renal Insufficiency: A Systematic Review and Meta-AnalysisHepatology, 2010
- Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trialLiver Transplantation, 2009
- Calcineurin Inhibitor NephrotoxicityClinical Journal of the American Society of Nephrology, 2009
- Early renal function post-liver transplantation is predictive of progressive chronic kidney disease.Scandinavian Journal of Gastroenterology, 2008
- Chronic Renal Failure after Transplantation of a Nonrenal OrganNew England Journal of Medicine, 2003